The purpose of this study is to see if a test medicine not yet approved for market, named Rifaximin SSD-40IR given Twice Daily, will help to delay the first episode of overt hepatic encephalopathy (OHE) requiring hospitalization, in patients with liver cirrhosis and how safe it is to use in people. Hepatic encephalopathy is a nervous system disorder caused by a buildup of toxins in the blood when the liver does not work properly. Participation in the study will last about 80 weeks, including the screening period which can last up to 28 days, followed by a 72-week treatment period and 4 week follow up period. This will involve 14 visits to be completed at the participant's study doctor’s clinic or at home every 4 to 8 weeks. Participants will be compensated $50.00 for each completed study.

You may be eligible for this study if you meet the following criteria:

• Conditions: Liver,Cirrhosis
• Age: 18 years - 85 years
• Gender: All